ReVivo Medical completed its most recent equity offering, raising $1.3 million.
“We believe the funds raised will be sufficient to complete our clinical trial and petition the FDA for clearance of our next generation spinal implants,” explains Gary Mittleman, President and CEO. “The $1.3 million of subscriptions came entirely from our current shareholders and their families.”
“Attaining FDA clearance is the final step before offering a commercial product and this trial is our gateway to achieving this goal,” says Eric Ledet, Chief Operating Officer. “Thus far, we have conducted 33 of the 50 surgical procedures required for the completion of the clinical study.”
ReVivo Medical completed its most recent equity offering, raising $1.3 million.
“We believe the funds raised will be sufficient to complete our clinical trial and petition the FDA for clearance of our next generation spinal implants,” explains Gary Mittleman, President and CEO. “The $1.3 million of subscriptions came entirely from our current...
ReVivo Medical completed its most recent equity offering, raising $1.3 million.
“We believe the funds raised will be sufficient to complete our clinical trial and petition the FDA for clearance of our next generation spinal implants,” explains Gary Mittleman, President and CEO. “The $1.3 million of subscriptions came entirely from our current shareholders and their families.”
“Attaining FDA clearance is the final step before offering a commercial product and this trial is our gateway to achieving this goal,” says Eric Ledet, Chief Operating Officer. “Thus far, we have conducted 33 of the 50 surgical procedures required for the completion of the clinical study.”
Copy to clipboard 
